Calcineurin Inhibitor–Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report

• Published in: Transplantation proceedings 2017-01, Vol.49 (1), p.163-166
• Main Authors: Ishida, S, Kato, M, Fujita, T, Funahashi, Y, Sassa, N, Matsukawa, Y, Yoshino, Y, Yamamoto, T, Katsuno, T, Maruyama, S, Gotoh, M
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Arthralgia - chemically induced; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Blood Group Incompatibility; Calcineurin Inhibitors - adverse effects; Cyclosporine - therapeutic use; Female; Graft Rejection - prevention & control; Graft Survival; Humans; Immunologic Factors - therapeutic use; Immunosuppressive Agents - therapeutic use; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - surgery; Kidney Transplantation; Middle Aged; Mycophenolic Acid - therapeutic use; Plasmapheresis; Preoperative Care; Recombinant Fusion Proteins - therapeutic use; Rituximab - therapeutic use; Sulfasalazine - therapeutic use; Surgery; Tacrolimus - adverse effects
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2016.11.007

Abstract Background Calcineurin-inhibitor–induced pain syndrome (CIPS) was used as a reference in the literature as reflex sympathetic dystrophy syndrome related to calcineurin inhibitors. Much of the literature describes CIPS that occurred after kidney and bone marrow transplantation. We describe a rare case of CIPS in induction immunosuppression before kidney transplantation, under administration of an anti-rheumatoid drug. Methods A 53-year-old woman had pre-status of ABO-incompatible living kidney transplantation. The patient had rheumatoid arthritis, but that was well-controlled with salazosulfapyridine as an anti-rheumatoid drug. Fourteen days before transplantation, she received induction immunosuppressive therapy consisting of tacrolimus (TAC) and mycophenolate mofetil (MMF) and she stopped taking salazosulfapyridine. The third day after that treatment, she had a high fever, fatigue, and joint pains of the knees, elbows, and wrists. Results When the patient stopped taking TAC and MMF and started taking salazosulfapyridine again, she soon recovered. Next, we challenged same induction immunosuppression therapy with administration of salazosulfapyridine; however, the patient had the same symptom. We considered that the symptom was caused by TAC or MMF, and we did not challenge-test each drug. We found that taking only TAC caused the same symptom for the patient. Also, we challenged cyclosporine (CsA) with MMF and confirmed that she did not have the symptom. Conclusions We decided that drugs of the induction immunosuppression therapy were CsA, MMF, prednisolone, and basiliximab. The patient received induction therapy with plasmapheresis and rituximab in addition to the above-mentioned drugs, and we performed ABO-incompatible kidney transplantation for her. The post-surgical course was good, without acute rejection, and she had no pain.